Glucagon-like peptide 1 receptor agonists and uses thereof

By modifying GLP1 amino acids and fusing with the stabilizing domain, the GLP1 receptor agonist against DPP4 is formed, which solves the problem of short half-life of existing GLP1 receptor agonists in vivo, and achieves long-term effective blood sugar control and insulin secretion. Enhanced.

CN118955732APending Publication Date: 2024-11-15REGENERON PHARMACEUTICALS INC
View PDF 24 Cites 0 Cited by

Patent Information

Application Number
CN202410964216.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-09-22
Filing Date
2018-09-21
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing glucagon-like peptide 1 (GLP1) receptor agonists have a short half-life in the body and are easily degraded by dipeptidyl peptidase 4 (DPP4), resulting in insufficient blood sugar control effectiveness and inability to effectively reduce blood sugar levels in the long term.

Method used

By performing amino acid modification on GLP1, adding amino acids or deleted amino acids to the N-terminus, and fusing with stabilizing domains such as antibodies or antigen-binding fragments thereof, a more stable GLP1 receptor agonist is formed to increase resistance to DPP4 and Serum half-life.

Benefits of technology

It has achieved that GLP1 receptor agonist significantly reduces blood sugar levels for more than 10 days in a single dose, enhances glucose-induced insulin secretion and blood sugar control effects, and prolongs its activity in the body. It is suitable for the treatment of obesity and diabetes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention relates to glucagon-like peptide 1 receptor agonists and uses thereof, and particularly provides modified glucagon-like peptide 1 (GLP1) polypeptides, fusion proteins comprising the modified GLP1 polypeptides, and methods of use thereof. In various embodiments of the invention, the fusion protein is a GLP1 receptor agonist comprising a modified GLP1 fused to a stabilizing domain. In some embodiments, fusion proteins comprising modified GLP1 may be used to treat or ameliorate symptoms or indications of diseases such as obesity and diabetes.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese patent application with application number 201880061327.6 and invention name “Glucagon-like peptide 1 receptor agonists and uses thereof”. The original application is the PCT international application PCT / US2018 / 052110 filed on September 21, 2018, which entered the Chinese national phase on March 20, 2020. Technical Field

[0002] The present invention relates to a human glucagon-like peptide 1 receptor agonist and a therapeutic method using the agonist. Background Art

[0003] Obesity has become a major health problem in the United States, with two-thirds of Americans considered overweight or obese. Obesity is an important underlying risk factor for developing other diseases, such as heart disease, stroke, and diabetes. Even a modest weight loss (5% to 10% of initial body weight) reduces the risk of obesity-related diseases, such as heart disease and diabetes.

[0004] Diabetes is a chronic condition characterized by high blood sugar levels and insulin resistance. If untreated, high blood sugar levels can lead to long-term complications, including heart disease, stroke, diabetic retinopathy, and lower limb amputations. Treatment of diabetes involves controlling and lowering blood sugar levels, and includes exercise and dietary modifications as well as medications such as insulin and metformin.

[0005] One of the methods for treating obesity and for blood sugar control involves glucagon-like peptide (GLP)-1 receptor agonists targeting the incretin pathway. Glucagon-like peptide (GLP)-1 is a peptide hormone secreted by enteroendocrine cells. After oral glucose administration, GLP1 binds to its receptor, resulting in insulin secretion and reduced blood sugar levels (incretin effect). However, the enzyme dipeptidyl peptidase 4 (DPP4) rapidly inactivates and degrades GLP1, and GLP1 has a very short half-life of 1.5 minutes. Therefore, longer-acting derivatives of GLP1 and GLP1 receptor agonists (including fusion proteins containing GLP1) have been studied for diabetes control. GLP1 analogs, fusion proteins and GLP1 receptor agonists are disclosed in, for example, US7452966, US8389689, US8497240, US8557769, US8883447, US8895694, US9409966, US20160194371, US20140024586, US20140073563, US20120148586, US20170114115, US20170112904, US20160361390, US20150313908, US20150259416, WO2017074715, WO2016127887, WO2015021871, WO2014113357, EP3034514, EP2470198 and EP2373681.

[0006] However, there is a need for new GLP1 peptide variants and GLP1 receptor agonists that are resistant to degradation by DPP4, have improved pharmacokinetic properties, and have increased potency and sustained in vivo activity in glycemic control. Such GLP1 variants and GLP1 receptor agonists can be used to treat obesity and diabetes. Summary of the invention

[0007] According to one aspect, the present invention provides a glucagon-like peptide 1 (GLP1) variant comprising at least one amino acid modification from mature GLP1 (7-37) (SEQ ID NO: 4), wherein the amino acid modification is selected from: (i) adding an amino acid to the N-terminus; and (ii) deleting an amino acid from the peptide sequence. In certain embodiments, the modification comprises adding alanine or glutamine to the N-terminus.

[0008] According to one aspect, the present invention provides a GLP1 receptor agonist, wherein the GLP1 receptor agonist comprises a fusion protein containing GLP1 or a variant thereof. In certain embodiments, the GLP1 receptor agonist comprises a GLP1 peptide or a GLP1 peptide variant fused to a stabilizing domain. In one embodiment, the stabilizing domain is an antibody or an antigen-binding fragment thereof that binds to the GLP1 receptor.

[0009] The GLP1 receptor agonists of the present invention are particularly useful for increasing the binding and / or activity of GLP1. In some embodiments, the GLP1 receptor agonists of the present invention act by activating GLP1 and lowering blood glucose levels. In some embodiments, the GLP1 peptide variants and / or GLP1 receptor agonists of the present invention are more resistant to inactivation by dipeptidyl peptidase 4 (DPP4) and show improved in vivo half-life. The improved GLP1 agonists of the present invention lead to a significant reduction in blood glucose levels, which is maintained for more than 10 days even with a single dose. In some embodiments, the GLP1 receptor agonists act by enhancing glucose-induced insulin secretion from pancreatic β cells, increasing insulin expression, inhibiting β cell apoptosis, promoting β cell regeneration, reducing glucagon secretion, delaying gastric emptying, promoting satiety, and improving peripheral glucose disposal. In certain embodiments, GLP1 receptor agonists can be used to prevent, treat, or improve at least one symptom of a hyperglycemia-related disease or disorder (e.g., diabetes) in a subject. In certain embodiments, a GLP1 receptor agonist may be administered prophylactically or therapeutically to a subject suffering from or at risk of diabetes. In certain embodiments, GLP1 receptor agonists can be used to prevent, treat, or ameliorate at least one symptom or indication of obesity, such as weight loss, in a subject.

[0010] In certain embodiments, the GLP1 receptor agonist is a fusion protein comprising a GLP1 variant and a stabilizing domain, wherein the stabilizing domain comprises an immunoglobulin or a fragment thereof. In a specific embodiment, the immunoglobulin comprises a heavy chain variable region and a light chain variable region, and specifically binds to the GLP1 receptor. In certain embodiments, the GLP1 receptor agonist binds to the GLP1 receptor, thereby causing GLP1 receptor activation. In certain embodiments, the GLP1 receptor agonist exerts its effect by activating the GLP1 receptor, thereby causing blood sugar control (i.e., lowering blood sugar levels).

[0011] In one embodiment, the present invention provides a fusion protein having one or more of the following features: (a) comprising a GLP1 variant domain and a stabilizing domain; (b) being a GLP1 receptor agonist; (c) the GLP1 variant domain comprising the amino acid sequence of SEQ ID NO: 5, 6, 7 or 8; (d) binding to the GLP1 receptor; (e) the stabilizing domain comprising an immunoglobulin or a fragment thereof; (f) the stabilizing domain comprising an immunoglobulin Fc fragment; (g) the stabilizing domain comprising an anti-GLP1 receptor antibody or an antigen-binding fragment thereof; (h) resisting degradation by serum proteases for at least 72 hours; and (i) significantly reducing serum glucose levels, which persists for more than 10 days under single dose administration.

[0012] In one aspect, the present invention provides a nucleic acid molecule encoding a GLP1 variant or a portion thereof. For example, the present invention provides a nucleic acid molecule encoding any amino acid sequence selected from SEQ ID No: 5, 6, 7, 8, 9, 10, 11, 12 and 13, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

[0013] The present invention also provides nucleic acid molecules encoding any fusion protein comprising a GLP1 variant.

[0014] In a related aspect, the present invention provides a recombinant expression vector capable of expressing a polypeptide comprising a GLP1 variant or a fusion protein comprising a GLP1 variant as described herein. For example, the present invention includes a recombinant expression vector containing any of the above-mentioned nucleic acid molecules (i.e., a nucleic acid molecule encoding any GLP1 variant or a fusion protein comprising a GLP1 variant). Also included within the scope of the present invention are host cells into which such vectors have been introduced, as well as methods for producing proteins or fragments thereof by culturing host cells under conditions that allow the production of proteins or fragments thereof and recovering the proteins and fragments so produced.

[0015] In one aspect, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of at least one recombinant protein or fragment thereof that specifically binds to a GLP1 receptor and a pharmaceutically acceptable carrier. In a related aspect, the present invention features a composition that is a combination of a GLP1 receptor agonist protein and a second therapeutic agent. In one embodiment, the second therapeutic agent is any agent that is advantageously combined with a GLP1 receptor agonist. Exemplary agents that may be advantageously combined with a GLP1 receptor agonist include, but are not limited to, other agents that activate GLP1 receptor activity (including other proteins or metabolites, etc.) and / or agents that do not directly bind to the GLP1 receptor but still alleviate or improve or treat GLP1 receptor-related diseases or conditions (e.g., diabetes). Other combination therapies and co-formulations involving the GLP1 receptor agonist proteins of the present invention are disclosed elsewhere herein.

[0016] On the other hand, the present invention provides a method for treating a GLP1-related disease or condition (e.g., diabetes) in a subject using a GLP1 receptor agonist of the present invention, wherein the method comprises administering a therapeutically effective amount of a pharmaceutical composition comprising a GLP1 receptor agonist of the present invention to a subject in need thereof. In certain embodiments, the GLP1 receptor agonist comprises a GLP1 variant or a fusion protein comprising a GLP1 variant. The disease being treated is any disease or condition that is improved, alleviated, inhibited, or prevented by activating the activity of the GLP1 receptor. In certain embodiments, the present invention provides a method for preventing, treating, or ameliorating at least one symptom of a GLP1 receptor-related disease or condition, the method comprising administering a therapeutically effective amount of a GLP1 receptor agonist of the present invention to a subject in need thereof. In some embodiments, the present invention provides a method for improving or reducing the severity of at least one symptom or indication of a GLP1 receptor-related disease or disorder in a subject by administering a therapeutically effective amount of a GLP1 receptor agonist protein of the present invention, wherein the at least one symptom or indication is selected from: high blood sugar levels, excessive thirst, increased urination, presence of ketones in urine, fatigue, weight fluctuation, blurred vision, slow healing sores, frequent infections, swollen or tender gums, obesity, heart disease, stroke, kidney disease, eye disease, nerve damage, and high blood pressure. In certain embodiments, the present invention provides a method for reducing weight in an overweight or obese subject, the method comprising administering to the subject a therapeutically effective amount of a GLP1 receptor agonist of the present invention, which binds to the GLP1 receptor and activates GLP1 receptor activity. In certain embodiments, the present invention provides a method for lowering blood glucose levels in a subject, the method comprising administering to the subject a therapeutically effective amount of a GLP1 receptor agonist of the present invention, which binds to the GLP1 receptor and activates GLP1 receptor activity. In some embodiments, the GLP1 receptor agonist may be administered prophylactically or therapeutically to a subject suffering from or at risk of hyperglycemia. Subjects at risk include, but are not limited to, elderly subjects, pregnant women, subjects with high HbA1c levels, and subjects with one or more risk factors including obesity, high blood cholesterol, smoking, excessive drinking, and / or lack of exercise. In certain embodiments, the present invention provides a method for treating type 2 diabetes that cannot be controlled by treatment with insulin and / or metformin, the method comprising administering to a subject in need thereof a therapeutically effective amount of a GLP1 receptor agonist of the present invention.In certain embodiments, the GLP1 receptor agonist of the present invention is administered in combination with a second therapeutic agent to a subject in need thereof. The second therapeutic agent can be selected from: insulin or insulin analogs, biguanides (e.g., metformin), thiazolidinediones, sulfonylureas (e.g., chlorpropamide), glinides (e.g., nateglinide), alpha glucosidase inhibitors, DPP4 inhibitors (e.g., sitagliptin), pramlintide, bromocriptine, SGLT2 inhibitors (e.g., canagliflozin), antihypertensives, statins, aspirin, diatary modification, exercise, and dietary supplements. Additional therapeutic agents that can be used in combination with the GLP1 receptor agonist fusion proteins of the present invention are described elsewhere herein. In certain embodiments, the second therapeutic agent may be an agent that helps to offset or reduce any possible side effects associated with the GLP1 receptor agonist of the present invention (if such side effects occur). The GLP1 receptor agonist may be administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly or intracranially. The GLP1 receptor agonist may be administered at a dose of about 0.1 mg / kg of the subject's body weight to about 100 mg / kg of the subject's body weight. In certain embodiments, the GLP1 receptor agonist of the present invention may be administered at one or more doses comprising 0.1 mg to 600 mg.

[0017] The invention also includes the use of a GLP1 receptor agonist of the invention in the preparation of a medicament for treating a disease or condition that would benefit from stimulation of GLP1 receptor binding and / or activity (eg, diabetes, including type 2 diabetes).

[0018] Still other embodiments will become apparent upon reading the following detailed description. DETAILED DESCRIPTION

[0019] Before describing the inventive method, it should be understood that the present invention is not limited to the specific methods and experimental conditions described, because such methods and conditions can vary. It should also be understood that the terms used herein are only for the purpose of describing some specific embodiments, and are not intended to be limiting, because the scope of the present invention will only be limited by the appended claims.

[0020] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, some preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference in their entirety.

[0021] definition

[0022] The term "GLP1", also known as "glucagon-like peptide 1", refers to a 31-amino acid peptide hormone released by intestinal L cells after consuming nutrients. GLP1 binds to the GLP1 receptor and enhances glucose-induced insulin secretion from pancreatic β cells, increases insulin expression, inhibits β cell apoptosis, promotes β cell neogenesis, reduces glucagon secretion, delays gastric emptying, promotes satiety, and improves peripheral glucose disposal. In certain embodiments, the term "GLP1" refers to a mature 31-amino acid peptide hormone (SEQ ID NO: 4), which comprises amino acids 7 to 37 of the full-length GLP1 peptide (SEQ ID NO: 3). The term also includes variants of GLP1, wherein the variant comprises 1, 2, 3, 4, 5 or 6 amino acid substitutions, additions or deletions. For example, the term includes variants comprising the amino acid sequence of SEQ ID NO: 5, 6, 7 or 8.

[0023] As used herein, a "stabilizing domain" is any macromolecule that, when fused to a peptide, increases the in vivo activity and / or stability of the peptide. For example, a stabilizing domain may be a protein comprising an immunoglobulin C H3 domains. In certain embodiments, the stabilizing domain improves the serum half-life of the peptide. In certain embodiments, the stabilizing peptide improves the in vivo effectiveness of the peptide. A non-limiting example of a stabilizing domain is the Fc portion of an immunoglobulin, such as the Fc domain of an IgG, the IgG being selected from isotypes IgG1, IgG2, IgG3 and IgG4, and any allotype within each isotype group. In certain embodiments, the stabilizing domain is an amino acid sequence or Fc fragment having a length of 1 to about 200 amino acids comprising at least one cysteine ​​residue. As another example, the stabilizing domain can be an immunoglobulin or an antigen-binding fragment thereof. In certain embodiments, the stabilizing domain is an immunoglobulin comprising a heavy chain variable region and a light chain variable region, wherein the immunoglobulin binds to a specific antigen. In certain embodiments, the stabilizing domain comprises an antigen-binding domain and an Fc domain (e.g., of an IgG1 or IgG4 antibody) or may comprise only an antigen-binding portion (e.g., Fab, F(ab')2 or scFv fragment), and may be modified to affect function. In a specific embodiment, the stabilizing domain is an immunoglobulin comprising a heavy chain variable region and a light chain variable region, wherein the immunoglobulin binds to a GLP1 receptor. In other embodiments, the stabilizing domain is a cysteine ​​residue or a short cysteine-containing peptide. Other stabilizing domains include peptides or polypeptides comprising or consisting of a leucine zipper, a helix-loop motif, or a coiled coil motif.

[0024] The term "GLP1 receptor agonist" as used herein refers to a protein that binds to the GLP1 receptor. In the context of the present invention, the term refers to a fusion protein comprising GLP1 or a GLP1 variant fused to a stabilizing domain. In certain embodiments, the term includes a fusion protein comprising a GLP1 variant fused to an immunoglobulin or a fragment thereof. In a specific embodiment, the term includes a fusion protein comprising GLP1 or a GLP1 variant fused to the N-terminus of the light chain variable region (VL) of an immunoglobulin. In a specific embodiment, the term includes GLP1 or a GLP1 variant fused to the N-terminus of the VL of an antibody or antigen-binding fragment thereof that binds to the GLP1 receptor.

[0025] The term "antibody" as used herein is intended to refer to an immunoglobulin molecule or antigen-binding fragment thereof comprising four polypeptide chains (two heavy (H) chains and two light (L) chains) interconnected by disulfide bonds and multimers thereof (e.g., IgM). Each heavy chain comprises a heavy chain constant region (which comprises domain C H 1. C H 2 and C H3) and an Ig variable region, which may be a heavy chain variable region ("HCVR" or "V H ”) or light chain variable region (light chain variable region, “LCVR or “V L Each light chain comprises a light chain variable region ("LCVR" or "V L ”) and the light chain constant region (C L ). H and V L The V region can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). H and V L Each comprises three CDRs and four FRs, which are arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In certain embodiments of the present invention, the FRs of the antibody (or its antigen-binding fragment) may be identical to human germline sequences, or may be natural or artificially modified. The amino acid consensus sequence may be defined based on parallel analysis of two or more CDRs. The term "antigen-binding protein" as used herein also includes antibodies.

[0026] The substitution of one or more CDR residues or the omission of one or more CDRs are also possible. The following antibodies have been described in the scientific literature, in which one or two CDRs can be exempted from binding. Padlan et al. (1995 FASEB J. 9: 133-139) analyzed the contact area between the antibody and its antigen based on the disclosed crystal structure, and concluded that only about one-fifth to one-third of the CDR residues actually contact the antigen. Padlan also found many following antibodies, in which the amino acids of one or two CDRs do not contact the antigen (see also Vajdos et al. 2002 J Mol Biol 320: 415-428).

[0027] Methods and techniques for identifying CDRs in VR amino acid sequences are well known in the art and can be used to identify CDRs in the specific VR amino acid sequences disclosed herein. Exemplary conventions that can be used to identify the boundaries of CDRs include, for example, the Kabat definition, the Chothia definition, and the AbM definition. In general, the Kabat definition is based on sequence variability, the Chothia definition is based on the location of the structural loop regions, and the AbM definition is a compromise between the Kabat approach and the Chothia approach. See, for example, Kabat, "Sequences of Proteins of Immunological Interest," National Institutes of Health, Bethesda, Md. (1991); Al-Lazikani et al., J. Mol. Biol. 273:927-948 (1997); and Martin et al., Proc. Natl. Acad. Sci. USA 86:9268-9272 (1989). Public databases can also be used to identify CDR sequences in the antigen binding domain of an antigen binding protein or antibody.

[0028] CDR residues that do not contact the antigen can be identified based on previous studies (e.g., residues H60-H65 in CDRH2 are generally not required), excluding Chothia CDRs from the region of Kabat CDRs, by molecular modeling, and / or empirically. If a CDR or its residues are omitted, they are typically replaced with an amino acid occupying the corresponding position in another human antibody sequence or a consensus sequence of such sequences. The replacement position in the CDR and amino acid to be replaced can also be selected empirically. Empirical replacements can be conservative replacements or non-conservative replacements.

[0029] As used herein, the terms "antigen-binding portion of an antigen-binding protein", "antigen-binding fragment of an antigen-binding protein", etc. include any naturally occurring, enzymatically obtainable, synthetic or genetically modified polypeptide or glycoprotein that specifically binds to an antigen to form a complex. As used herein, the term "antigen-binding fragment of an antigen-binding protein" or "antigen-binding protein fragment" refers to one or more fragments of an antigen-binding protein that retain the ability to specifically bind to a GLP1 receptor. Antigen-binding protein fragments may include Fab fragments, F(ab')2 fragments, Fv fragments, dAb fragments, fragments containing CDRs, or isolated CDRs. In certain embodiments, the term "antigen-binding fragment" refers to a polypeptide fragment of a multispecific antigen-binding molecule. Antigen-binding fragments of antigen-binding proteins or antibodies can be obtained, for example, from whole protein molecules using any suitable standard techniques, such as proteolytic digestion or recombinant genetic modification techniques, which involve the manipulation and expression of DNA encoding variable domains and (optionally) constant domains of antigen-binding proteins. Such DNA is known and / or can be readily obtained from, for example, commercial sources, DNA libraries (including, for example, phage antibody libraries), or can be synthesized. The DNA may be sequenced and manipulated chemically or by using molecular biology techniques, for example to arrange one or more variable and / or constant domains into an appropriate configuration, or to introduce codons, create cysteine ​​residues, modify, add or delete amino acids, and the like.

[0030] Some non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) the smallest recognition unit consisting of amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated complementary determining region (CDR), such as a CDR3 peptide), or a constrained FR3-CDR3-FR4 peptide. Other modified molecules, such as domain-specific antibodies, single-domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs) and shark variable IgNAR domains are also encompassed within the expression "antigen-binding fragment" as used herein.

[0031] The antigen-binding protein or antigen-binding fragment of an antibody of the present invention generally comprises at least one immunoglobulin (Ig) variable domain. The variable domain may have any size or amino acid composition and generally comprises at least one CDR that is adjacent to or in frame with one or more framework sequences. L Domain-associated V H In the antigen-binding fragment of the structural domain, V H and V L The domains may be positioned relative to each other in any suitable arrangement. For example, the variable region may be a dimer and include V H -V H 、V H -V L or V L -V L Alternatively, the antigen binding fragment of the antigen binding protein may comprise a monomer V H or V L Structural domain.

[0032] In certain embodiments, the antigen-binding fragment may comprise at least one variable domain covalently linked to at least one constant domain. Some non-limiting exemplary configurations of variable and constant domains that may be present in the antigen-binding fragments of the antibodies of the invention include: (i) V H -C H 1; (ii) V H -C H 2; (iii) V H -C H 3; (iv) V H -C H 1-C H 2; (v) V H -C H 1-C H 2-C H 3; (vi) V H -C H 2-C H 3; (vii) V H -C L ; (viii) V L -C H 1; (ix) V L -C H 2; (x) V L -C H 3; (xi) V L -C H 1-C H 2; (xii) V L -C H 1-C H 2-CH 3; (xiii) V L -C H 2-C H 3; and (xiv) V L -C L . In any configuration of variable domains and constant domains (including any of the exemplary configurations listed above), the variable domains and constant domains may be directly connected to each other, or may be connected through a complete or partial hinge region or linker region. The hinge region may be composed of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids, which results in a flexible or semi-flexible connection between adjacent variable domains and / or constant domains in a single polypeptide molecule. In addition, the antigen-binding fragments of the antigen-binding proteins of the present invention may contain each other and / or one or more monomeric V H or V L Homodimers or heterodimers (or other multimers) of any of the variable and constant domain configurations listed above in which the domains are non-covalently associated (e.g., via disulfide bonds).

[0033] As with complete protein molecules, antigen-binding fragments can be monospecific or multispecific (e.g., bispecific). Multispecific antigen-binding fragments of antigen-binding proteins typically contain at least two different variable domains, each of which is capable of specifically binding to a separate antigen or to a different epitope on the same antigen. Conventional techniques available in the art can be used to make any multispecific antigen-binding protein format (including the exemplary bispecific antigen-binding protein formats disclosed herein) suitable for use in the case of antigen-binding fragments of antigen-binding proteins of the present invention.

[0034] The terms "fully human antibodies", "human antibodies", "fully human antigen-binding proteins" or "human antigen-binding proteins" used herein are intended to include antigen-binding proteins with variable regions and constant regions derived from human germline immunoglobulin sequences. The human antigen-binding proteins of the present invention may, for example, include amino acid residues not encoded by human germline immunoglobulin sequences in CDR and particularly CDR3 (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutations in vivo). However, the term "human antigen-binding proteins" used herein are not intended to include antigen-binding proteins in which CDR sequences derived from the germline of another mammalian species (e.g., mouse) have been grafted to human FR sequences. The term includes antigen-binding proteins or antibodies recombinantly produced in non-human mammals or in cells of non-human mammals. The term is not intended to include antigen-binding proteins or antibodies isolated from human subjects or produced in human subjects.

[0035] The term "recombinant" as used herein refers to a fusion protein of the present invention or a fragment thereof produced, expressed, separated or obtained by a technique or method known in the art as recombinant DNA technology (which includes, for example, DNA splicing and transgenic expression). The term refers to a fusion protein expressed in a non-human mammal (including a transgenic non-human mammal, such as a transgenic mouse) or cell (e.g., CHO cell) expression system or separated from a recombinant combinatorial human antibody library.

[0036] The term "specific binding" or "specifically binds to" means that the antibody or antigen-binding fragment thereof forms a relatively stable complex with the antigen under physiological conditions. Specific binding is characterized by an equilibrium dissociation constant of at least about 1x10 -8 M or smaller (e.g., K D Smaller means tighter binding). Methods for determining whether two molecules specifically bind are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, isothermal titration calorimetry, and the like.

[0037] As used herein, the terms "antigen binding portion" of an antibody, "antigen binding fragment" of an antibody, etc. include any naturally occurring, enzymatically obtainable, synthetic or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. As used herein, the terms "antigen binding fragment" of an antigen binding protein or antibody or "antibody fragment" refer to one or more fragments of an immunoglobulin protein that retain the ability to bind to the GLP1 receptor.

[0038] The term "K D ” refers to the equilibrium dissociation constant for a specific protein-antigen interaction.

[0039] The term "substantially identical" or "substantially identical" when referring to nucleic acids or fragments thereof means that the nucleotide sequences are identical in at least about 90%, more preferably at least about 95%, 96%, 97%, 98% or 99% of the nucleotide bases when optimally aligned with another nucleic acid (or its complementary strand) using appropriate nucleotide insertions or deletions, as measured, for example, by any well-known sequence identity algorithm, such as FASTA, BLAST or GAP as described below. In some cases, a nucleic acid molecule having substantial identity to a reference nucleic acid molecule can encode a polypeptide having the same or substantially similar amino acid sequence as a polypeptide encoded by the reference nucleic acid molecule.

[0040] When applied to polypeptides, the term "significant similarity" or "substantially similar" refers to two peptide sequences that have at least 90% sequence identity, even more preferably at least 95%, 98% or 99% sequence identity, when optimally aligned, for example, by the GAP or BESTFIT programs using default gap weights. Preferably, non-identical residue positions differ by conservative amino acid substitutions. "Conservative amino acid substitutions" are amino acid substitutions in which one amino acid residue is replaced by another amino acid residue with a side chain (R group) having similar chemical properties (e.g., charge or hydrophobicity). Generally speaking, conservative amino acid substitutions do not substantially change the functional properties of proteins. In the case where two or more amino acid sequences differ from each other by conservative substitutions, the percentage or degree of similarity may be raised to correct for the conservative nature of the substitution. The means for making such adjustments are well known to those skilled in the art. See, for example, Pearson (1994) Methods Mol. Biol. 24: 307-331, which is incorporated herein by reference. Some examples of amino acid groups with similar chemical properties in side chains include: 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic-hydroxy side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartic acid and glutamic acid, and 7) sulfur-containing side chains: cysteine ​​and methionine. Some preferred conservative amino acid substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. Alternatively, a conservative substitution is any change disclosed in Gonnet et al. (1992) Science 256:1443 45 (incorporated herein by reference) that has a positive value in the PAM250 log-likelihood matrix. A "moderately conservative" replacement is any change that has a non-negative value in the PAM250 log-likelihood matrix.

[0041] Sequence analysis software is usually used to measure the sequence similarity of polypeptides. Protein analysis software uses a similarity measure assigned to a variety of replacements, deletions and other modifications (including conservative amino acid replacements) to match similar sequences. For example, GCG software includes programs such as GAP and BESTFIT, which can be used with default parameters to determine the sequence homology or sequence identity between closely related polypeptides (for example, homologous polypeptides from different biological species) or between wild-type proteins and their mutant proteins. See, for example, GCG version 6.1. FASTA (the program in GCG version 6.1) can also be used to utilize default or recommended parameters to compare polypeptide sequences. FASTA (for example FASTA2 and FASTA3) provides the comparison between the query sequence and the search sequence and the percentage sequence identity of the best overlapping region (Pearson (2000), the same). When the sequence of the present invention is compared with a database comprising a large number of sequences from different organisms, another preferred algorithm is the computer program BLAST using default parameters, especially BLASTP or TBLASTN. See, e.g., Altschul et al. (1990) J. Mol. Biol. 215:403-410 and (1997) Nucleic Acids Res. 25:3389-3402, each of which is incorporated herein by reference.

[0042] The phrase "therapeutically effective amount" means an amount that produces the desired effect on a subject to which it is administered. The exact amount will depend on the purpose of the treatment and can be determined by one skilled in the art using known techniques (see, e.g., Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding).

[0043] The term "subject" as used herein refers to an animal, preferably a mammal, and more preferably a human, that needs to improve, prevent and / or treat a disease or condition associated with GLP1. The term includes human subjects suffering from a disease or condition associated with GLP1 or at risk of a disease or condition associated with GLP1. For example, the term includes subjects suffering from or at risk of developing diabetes (e.g., type 2 diabetes). In certain embodiments, the term includes subjects suffering from or at risk of developing obesity, stroke, or myocardial infarction. The term also includes subjects with high blood sugar levels and / or increased levels of one or more diabetes biomarkers (e.g., HbA1c). The term also includes subjects for whom standard treatment (e.g., metformin) is contraindicated or intolerant or who cannot control the disease despite treatment (e.g., with metformin).

[0044] The term "treatment" as used herein refers to the reduction or improvement of the severity of at least one symptom or indication of a disease or condition associated with GLP1 due to the administration of a therapeutic agent (e.g., a GLP1 receptor agonist of the present invention) to a subject in need thereof. The term includes inhibiting the progression of the disease or the worsening of symptoms. The term also includes a positive prognosis of the disease, that is, the subject may have no symptoms or indications or may have reduced symptom or indication intensity after the administration of a therapeutic agent (e.g., a GLP1 receptor agonist protein of the present invention). For example, a subject with diabetes may have a lower blood sugar level after the administration of a GLP1 receptor agonist of the present invention. The therapeutic agent may be administered to the subject in a therapeutic amount.

[0045] The term "prevention" refers to inhibiting the manifestation of any symptoms or indications of a disease or condition associated with hyperglycemia after administration of a GLP1 receptor agonist of the present invention. The term includes inhibiting the manifestation of symptoms or indications of such a disease or condition in a subject at risk of developing a GLP1 receptor-related disease or condition.

[0046] GLP1 (7-37) (SEQ ID NO: 4) has a very short half-life (1-2 minutes) in the circulation due to rapid inactivation by the enzyme dipeptidyl peptidase 4 (DPP4). Previous studies have shown that various amino acid substitutions at position 8 of GLP1 (7-37) make it more resistant to DPP4, thereby conferring a longer half-life. However, these molecules have residual sensitivity to DPP4 cleavage (Deacon et al 1998, Diabetologia 41: 271-278). Therefore, there is a need to develop new molecules with improved resistance to degradation by DPP4.

[0047] The inventors hypothesize that in order to confer better resistance to DPP4, the first step is to introduce mutations that extend or shorten the amino terminus of GLP1 by adding amino acids (i.e., Ala, Gln) to the N-terminus or deleting His or Ala in the peptide sequence to provide better resistance to DPP4 cleavage. The inventors have shown herein that these new GLP1 variants are indeed highly resistant to degradation by DPP4. The second step is to compensate for any weakened or reduced GLP1 activity by fusing GLP1 to anti-GLP1 receptor antibodies, which connect the weakened GLP1 to the GLP1 receptor and thereby increase its efficacy. In addition, the inventors found that these fusion proteins may have an extended serum half-life and result in enhanced reductions in blood glucose levels for more than 10 days, probably because they contain an Fc domain. As shown herein, the new GLP1 variants and fusion proteins disclosed herein have significantly improved resistance to degradation by DPP4 in vitro and in vivo, and show greatly improved efficacy in blood glucose control. In the case of resistance to degradation by DPP4, the term "significantly improved" or "enhanced" or "increased" as used herein refers to increased resistance to degradation that persists for more than 4 hours, more than 8 hours, more than 16 hours, more than 24 hours, more than 36 hours, or more than 70 hours after incubation with DPP4, for example as measured by an assay described herein. In the case of reduced blood glucose levels, the term "significantly improved" or "enhanced" or "increased" as used herein refers to a sustained reduction in blood glucose levels in a subject that persists for more than 1 day, more than 2 days, more than 3 days, more than 4 days, more than 5 days, more than 6 days, more than 7 days, more than 8 days, more than 9 days, or more than 10 days after administration of a GLP1 receptor agonist of the invention.

[0048] The GLP1 receptor agonists of the present invention bind to the GLP1 receptor with high affinity and cause activation of the GLP1 receptor. In some embodiments, the protein can be used to treat subjects with diabetes. The protein, when administered to a subject in need thereof, can reduce blood glucose levels in the subject. It can be used alone or as an adjunct therapy with other therapeutic moieties or methods known in the art for treating hyperglycemia.

[0049] Certain GLP1 receptor agonist proteins of the present invention are capable of binding to the GLP1 receptor and stimulating its activity, as determined by in vitro or in vivo assays. The ability of the proteins of the present invention to bind to the GLP1 receptor and enhance its activity can be measured using any standard method known to those skilled in the art, including binding assays or activity assays described herein.

[0050] The antigen binding protein having specificity for the GLP1 receptor may not contain an additional label or moiety, or it may contain an N-terminal or C-terminal label or moiety. In one embodiment, the label or moiety is biotin. In a binding assay, the position of the label (if any) can determine the orientation of the peptide relative to the surface to which the peptide is bound. For example, if the surface is coated with avidin, a peptide containing N-terminal biotin will be oriented so that the C-terminal portion of the peptide is distal to the surface. In one embodiment, the label can be a radionuclide, a fluorescent dye, or an MRI detectable label. In certain embodiments, such labeled antigen binding proteins can be used in diagnostic assays, including imaging assays.

[0051] Bioequivalent

[0052] The GLP1 receptor agonists of the present invention encompass proteins having an amino acid sequence that is different from the amino acid sequence of the GLP1 receptor agonist but retains the ability to bind to the GLP1 receptor. When compared to the parent sequence, such variant GLP1 receptor agonists contain one or more amino acid additions, deletions or substitutions, but exhibit biological activity substantially equivalent to the biological activity of the GLP1 receptor agonist. Similarly, the DNA sequence encoding the GLP1 receptor agonist of the present invention encompasses a sequence that contains one or more nucleotide additions, deletions or substitutions compared to the disclosed sequence but encodes a GLP1 receptor agonist that is substantially bioequivalent to the GLP1 receptor agonist of the present invention.

[0053] If, for example, two proteins are pharmaceutical equivalents or pharmaceutical substitutes that do not show significant differences in the rate and extent of absorption when administered at the same molar dose as a single or multiple dose under similar experimental conditions, they are considered bioequivalent. If some proteins are equivalent in their extent of absorption but not in their rate of absorption, they will be considered equivalents or pharmaceutical substitutes and may still be considered bioequivalent because such differences in absorption rate are intentional and reflected in the labeling, are not essential to achieving effective in vivo drug concentrations, for example in chronic use, and are not considered medically significant for the particular drug product under study.

[0054] In one embodiment, two GLP1 receptor agonist proteins are bioequivalent if there are no clinically meaningful differences in their safety, purity, or potency.

[0055] In one embodiment, two GLP1 receptor agonist proteins are bioequivalent if patients can switch between the reference product and the biological product one or more times without an increased risk of expected adverse effects (including clinically significant changes in immunogenicity, or reduced effectiveness) compared to continued treatment without such switching.

[0056] In one embodiment, two GLP1 receptor agonist proteins are bioequivalent if they act by one or more common mechanisms of action according to one or more conditions of use to the extent such mechanisms are known.

[0057] Bioequivalence can be demonstrated by in vivo and / or in vitro methods. Bioequivalence measurements include, for example: (a) in vivo testing in humans or other mammals, where the concentration of the protein or its metabolites is measured in blood, plasma, serum or other biological fluids as a function of time; (b) in vitro testing that correlates with and is reasonably predictive of human in vivo bioavailability data; (c) in vivo testing in humans or other mammals, where the appropriate acute pharmacological effects of the protein (or its target) are measured as a function of time; and (d) in well-controlled clinical trials that establish the safety, efficacy, or bioavailability or bioequivalence of the antigen binding protein.

[0058] Bioequivalent variants of the GLP1 receptor agonist proteins of the present invention can be constructed by, for example, making multiple substitutions of residues or sequences or deleting terminal or internal residues or sequences that are not required for biological activity. For example, cysteine ​​residues that are not required for biological activity can be deleted or replaced by other amino acids to prevent the formation of unnecessary or incorrect intramolecular disulfide bridges during renaturation. In other cases, bioequivalent proteins may include variants comprising amino acid changes that change the glycosylation characteristics of the protein, such as mutations that eliminate or remove glycosylation.

[0059] Biological properties of GLP1 receptor agonists

[0060] In general, the GLP1 receptor agonists of the present invention act by binding to the GLP1 receptor and promoting the activation of the GLP1 receptor after binding. In certain embodiments, the proteins of the present invention bind to the GLP1 receptor with high affinity. For example, the present invention includes GLP1 receptor agonists that cause GLP1 receptor activation (e.g., at 25° C. or at 37° C.), as measured by a luciferase assay, for example, using the assay format defined in Example 2 herein. In certain embodiments, the GLP1 receptor agonist activates the GLP1 receptor with an EC50 of less than 10 nM, less than 500 pM, or less than 250 pM, as measured by a luciferase assay, for example, using the assay format defined in Example 2 herein, or a substantially similar assay.

[0061] The present invention also includes GLP1 receptor agonists that reduce blood glucose levels in vivo after administration to a subject in need thereof, for example as shown in Example 3 or a substantially similar assay. The GLP1 receptor agonist achieves enhanced glycemic control after administration, resulting in reduced blood glucose levels. In certain embodiments, even a single therapeutically effective dose of the GLP1 receptor agonist of the present invention results in a significant reduction in blood glucose that lasts for more than 10 days.

[0062] The invention also includes GLP1 receptor agonists that exhibit increased resistance to degradation by serum proteases / peptidases, as measured by mass spectrometry (e.g., as shown in Example 4 herein) or a substantially similar method. In certain embodiments, the GLP1 receptor agonist resists degradation by dipeptidyl peptidase 4 (DPP4) for more than 4 hours, more than 6 hours, more than 12 hours, more than 24 hours, more than 48 hours, or more than 70 hours, as measured by the assay described in Example 4 herein.

[0063] The GLP1 receptor agonists of the present invention may have one or more of the above biological properties, or any combination thereof. Other biological properties of the proteins of the present invention will be apparent to those of ordinary skill in the art by reviewing the present disclosure, including the working examples herein.

[0064] Therapeutic administration and formulations

[0065] The present invention provides therapeutic compositions comprising the GLP1 receptor agonists of the present invention. The therapeutic compositions according to the present invention are administered together with suitable carriers, excipients and other agents introduced into the formulations to improve transfer, delivery, tolerance, etc. A large number of suitable formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) vesicles (e.g., LIPOFECTIN TM ), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsion carbowax (polyethylene glycol of different molecular weights), semisolid gels, and semisolid mixtures containing carbowax. See also Powell et al. "Compendium of excipients for parenteral formulations" PDA (1998) JPharm Sci Technol 52: 238-311.

[0066] The dosage of the GLP1 receptor agonist may vary according to the age and height of the subject to be administered, the target disease, condition, route of administration, and the like. When the antigen-binding protein of the present invention is used to treat a disease or condition in an adult patient, or to prevent such a disease, it is advantageous to generally administer the antigen-binding protein of the present invention in a single dose of about 0.001 to about 100 mg / kg body weight, more preferably about 0.001 to about 60, about 0.01 to about 10, or about 0.01 to about 1 mg / kg body weight. Depending on the severity of the disease, the frequency and duration of treatment may be adjusted. In certain embodiments, the antigen-binding protein of the present invention or its antigen-binding fragment may be administered at an initial dose of at least about 0.001 mg to about 100 mg, about 0.001 to about 50 mg, about 0.005 to about 50 mg, about 0.01 to about 40 mg, about 30 mg, or about 10 mg. In certain embodiments, a second or multiple subsequent doses of a GLP1 receptor agonist may be administered after the initial dose, and the amount may be approximately equal to or less than the amount of the initial dose, wherein the subsequent doses may be separated by at least 1 to 3 days; at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 9 weeks, at least 10 weeks, at least 12 weeks, or at least 14 weeks.

[0067] A variety of delivery systems are known and can be used to administer the pharmaceutical compositions of the invention, for example, encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing mutant viruses, receptor-mediated endocytosis (see, for example, Wu et al. (1987) J. Biol. Chem. 262: 4429-4432). Methods of introduction include, but are not limited to, intradermal, transdermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The composition can be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered with other bioactive agents. Administration can be systemic or local. The pharmaceutical composition can also be delivered in vesicles, particularly in liposomes (see, for example, Langer (1990) Science 249: 1527-1533).

[0068] The use of nanoparticles to deliver the GLP1 receptor agonists of the present invention is also contemplated herein. Protein-conjugated nanoparticles can be used for both therapeutic and diagnostic applications. Nanoparticles can be developed and conjugated to antigen-binding proteins contained in pharmaceutical compositions to target cells. Nanoparticles for drug delivery are also described in, for example, US 8257740 or US 8246995, each of which is incorporated herein in its entirety.

[0069] In some cases, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump can be used. In another embodiment, a polymeric material can be used. In another embodiment, the controlled release system can be placed near the target of the composition, so only a portion of the systemic dose is required.

[0070] Injectable preparations can include dosage forms for intravenous, subcutaneous, intradermal, intracranial, intraperitoneal and intramuscular injections, instillations, etc. These injectable preparations can be prepared by known methods. For example, injectable preparations can be prepared by, for example, dissolving, suspending or emulsifying the above-mentioned antigen-binding proteins or their salts in a conventional sterile aqueous medium or an oily medium for injection. As aqueous media for injection, there are, for example, physiological saline, isotonic solutions containing glucose and other adjuvants, etc., which can be used in combination with suitable solubilizers such as alcohol (for example, ethanol), polyols (for example, propylene glycol, polyethylene glycol), nonionic surfactants [for example, polysorbate 80, HCO-50 (polyoxyethylene (50 moles) adducts of hydrogenated castor oil)], etc. As oily media, use, for example, sesame oil, soybean oil, etc., which can be used in combination with solubilizers (for example, benzyl benzoate, benzyl alcohol, etc.). The injection thus prepared is preferably filled in a suitable ampoule.

[0071] The pharmaceutical compositions of the present invention can be delivered subcutaneously or intravenously with a standard needle and syringe. In addition, with respect to subcutaneous delivery, pen delivery devices are readily applicable to delivering the pharmaceutical compositions of the present invention. Such pen delivery devices can be reusable or disposable. Reusable pen delivery devices typically use a replaceable cartridge containing the pharmaceutical composition. Once all of the pharmaceutical composition within the cartridge has been administered and the cartridge is empty, the empty cartridge can be easily discarded and replaced with a new cartridge containing the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. In contrast, a disposable pen delivery device is pre-filled with a pharmaceutical composition contained in a reservoir within the device. Once the reservoir is empty of the pharmaceutical composition, the entire device is discarded.

[0072] Many reusable pen delivery devices and auto-injector delivery devices are available for subcutaneous delivery of the pharmaceutical compositions of the present invention. Examples include, but are certainly not limited to, AUTOPEN TM (Owen Mumford, Inc., Woodstock, UK), DISSETRONIC TM Pen (Disetronic Medical Systems, Burghdorf, Switzerland), HUMALOG MIX75 / 25 TM Pen, HUMALOG TM Pen, HUMALIN 70 / 30TM Pen (Eli Lilly and Co., Indianapolis, IN), NOVOPEN TM I, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIOR TM (NovoNordisk,Copenhagen,Denmark)、BD TM Pen (Becton Dickinson, Franklin Lakes, NJ), OPTIPEN TM 、OPTIPEN PRO TM 、OPTIPEN STARLET TM and OPTICLIK TM (Sanofi-Aventis, Frankfurt, Germany), etc. Examples of disposable pen delivery devices that can be used for subcutaneous delivery of the pharmaceutical compositions of the present invention include, but are certainly not limited to, SOLOSTAR TM Pen (Sanofi-Aventis), FLEXPEN TM (Novo Nordisk) and KWIKPEN TM (Eli Lilly), SURECLICK TM Autoinjector (Amgen, Thousand Oaks, CA), PENLET TM (Haselmeier, Stuttgart, Germany), EPIPEN (Dey, LP) and HUMIRA TM Pen (Abbott Labs, Abbott Park, IL), etc.

[0073] Advantageously, the above-mentioned pharmaceutical composition for oral or parenteral use is prepared into a unit dosage form suitable for matching a certain dose of active ingredient. Such unit dosage forms include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc. The amount of GLP1 receptor agonist contained in each unit dosage form is generally about 0.001 to about 100 mg; especially in the form of injection, preferably, the GLP1 receptor agonist is contained in about 0.001 to about 100 mg and about 0.01 to about 100 mg (for other dosage forms).

[0074] Therapeutic uses of GLP1 receptor agonists

[0075] The GLP1 receptor agonists of the present invention can be used to treat and / or prevent diseases or disorders or conditions associated with hyperglycemia, such as diabetes, and / or to improve at least one symptom associated with such diseases, disorders or conditions. In one embodiment, the GLP1 receptor agonists of the present invention can be administered to patients with diabetes (e.g., type 2 diabetes) at a therapeutic dose.

[0076] In certain embodiments, the GLP1 receptor agonists of the present invention can be used to treat a subject having a disease or condition selected from the group consisting of diabetes, obesity, insulin resistance, hypertension, dyslipidemia, type 2 diabetes, type 1 diabetes, prediabetes, cardiovascular disease, atherosclerosis, congestive heart failure, coronary heart disease, arteriosclerosis, peripheral arterial disease, stroke, respiratory dysfunction, kidney disease, fatty liver disease, non-alcoholic steatohepatitis (NASH) and metabolic syndrome.

[0077] In certain embodiments, the GLP1 receptor agonists of the invention may be used to treat overweight or obese subjects and / or to prevent or treat one or more obesity-related diseases, such as heart disease, stroke, and diabetes.

[0078] In certain embodiments, the GLP1 receptor agonists of the invention can be used to treat subjects with diabetes and / or prevent one or more complications of diabetes, such as heart disease, stroke, kidney disease, retinopathy, blindness, and nerve damage.

[0079] It is also contemplated herein to prophylactically use one or more GLP1 receptor agonist proteins of the invention in subjects at risk of developing diabetes (e.g., type 2 diabetes). Subjects at risk include, but are not limited to, elderly subjects, pregnant women, and subjects with one or more risk factors (including a family history of obesity, high blood cholesterol, smoking, excessive drinking, and / or lack of exercise).

[0080] In another embodiment, the protein of the invention is used to prepare a pharmaceutical composition or a medicament for treating a patient suffering from a disease or condition such as diabetes and obesity. In another embodiment of the invention, the GLP1 receptor agonist of the invention is used as an adjunct therapy with any other agent or any other treatment known to those skilled in the art to be useful for treating or ameliorating a disease or condition associated with hyperglycemia such as diabetes (e.g., type 2 diabetes).

[0081] Combination therapy

[0082] Combination therapy may comprise a GLP1 receptor agonist of the invention and any additional therapeutic agent that may be advantageously combined with a GLP1 receptor agonist of the invention or with a biologically active fragment thereof of the invention. The GLP1 receptor agonist of the invention may be synergistically combined with one or more drugs or treatments for the treatment of any disease or condition associated with hyperglycemia (e.g., diabetes). In some embodiments, the GLP1 receptor agonist of the invention may be combined with a second therapeutic agent to lower blood glucose levels in a subject, or to improve one or more symptoms of diabetes.

[0083] The GLP1 receptor agonists of the present invention can be used in combination with the following to treat or manage diabetes: insulin (insulin or insulin analogs), insulin sensitizers such as biguanides (e.g., metformin) and thiazolidinediones (e.g., rosiglitazone), insulin secretagogues such as sulfonylureas (e.g., chlorpropamide) and glinides (e.g., nateglinide), α-glucosidase inhibitors (e.g., acarbose), dipeptidyl peptidase 4 (DPP4) inhibitors (e.g., sitagliptin), pramlintide, bromocriptine, sodium glucose cotransporter 2 (sodium glucose cotransporter 3 ... sulfonylureas (e.g., chlorpropamide) and glinides (e.g., nateglinide), 2, SGLT-2) inhibitors (e.g., canagliflozin), antihypertensives (e.g., angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, calcium channel blockers, α-adrenergic receptor blockers, endothelin-1 receptor blockers, organic nitrates, and protein kinase C inhibitors), statins, aspirin, different GLP1 receptor agonists, dietary supplements, or any other treatment (e.g., exercise). In certain embodiments, the GLP1 receptor agonists of the present invention can be administered in combination with a second therapeutic agent or treatment selected from the group consisting of insulin, insulin analogs, metformin, rosiglitazone, pioglitazone, chlorpropamide, glibenclamide, glimepiride, glipizide, tolazamide, tolbutamide, nateglinide, repaglinide, acarbose, miglitol, exenatide, liraglutide, albiglutide, dulaglutide, sitagliptin, saxagliptin, linagliptin, alogliptin, pramlintide, immediate-release bromocriptine, quick-release), canagliflozin, dapagliflozin, empagliflozin, dietary modifications, and exercise.

[0084] As used herein, the term "in combination with" means that the additional therapeutically active component may be administered before, simultaneously or after the administration of the GLP1 receptor agonist of the present invention. The term "in combination with" also includes sequential or simultaneous administration of a GLP1 receptor agonist and a second therapeutic agent.

[0085] The additional therapeutically active component may be administered to the subject prior to administration of the GLP1 receptor agonist of the present invention. For example, if the first component is administered 1 week prior to administration of the second component, 72 hours prior to administration, 60 hours prior to administration, 48 hours prior to administration, 36 hours prior to administration, 24 hours prior to administration, 12 hours prior to administration, 6 hours prior to administration, 5 hours prior to administration, 4 hours prior to administration, 3 hours prior to administration, 2 hours prior to administration, 1 hour prior to administration, 30 minutes prior to administration, 15 minutes prior to administration, 10 minutes prior to administration, 5 minutes prior to administration, or less than 1 minute prior to administration of the first component, the first component may be considered to be administered "prior" to the second component. In other embodiments, the additional therapeutically active component may be administered to the subject after administration of the GLP1 receptor agonist of the present invention. For example, if the first component is administered 1 minute, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, or 72 hours after the administration of the second component, the first component may be considered to be administered "after" the second component. In other embodiments, the additional therapeutically active component may be administered to the subject at the same time as the GLP1 receptor agonist of the present invention. For purposes of the present invention, "simultaneous" administration includes, for example, administering the GLP1 receptor agonist and the additional therapeutically active component to the subject in a single dosage form, or administering them to the subject in separate dosage forms within about 30 minutes or less of each other. If administered in separate dosage forms, each dosage form may be administered by the same route (e.g., both the GLP1 receptor agonist and the additional therapeutically active component may be administered intravenously, etc.); alternatively, each dosage form may be administered by a different route (e.g., the GLP1 receptor agonist may be administered intravenously and the additional therapeutically active component may be administered orally). In any case, for the purposes of this disclosure, administration of the components in a single dosage form, in separate dosage forms by the same route, or in separate dosage forms by different routes are all considered to be "administered simultaneously." For the purposes of this disclosure, administration of a GLP1 receptor agonist "before," "concurrently," or "after" administration of an additional therapeutically active component (as these terms are defined above) is considered administration of the GLP1 receptor agonist "in combination" with the additional therapeutically active component.

[0086] The invention includes pharmaceutical compositions wherein the GLP1 receptor agonists of the invention are co-formulated with one or more additional therapeutically active ingredients as described elsewhere herein.

[0087] Administration regimen

[0088] According to certain embodiments, a single dose of the GLP1 receptor agonist of the present invention (or a pharmaceutical composition comprising a combination of a GLP1 receptor agonist and any additional therapeutically active agent mentioned herein) may be administered to a subject in need thereof. According to certain embodiments of the present invention, multiple doses of a GLP1 receptor agonist (or a pharmaceutical composition comprising a combination of a GLP1 receptor agonist and any additional therapeutically active agent mentioned herein) may be administered to a subject over a defined time course. The method according to this aspect of the present invention comprises sequentially administering multiple doses of a GLP1 receptor agonist of the present invention to a subject. "Sequential administration" as used herein refers to administering each dose of a GLP1 receptor agonist to a subject at different time points separated by a predetermined interval (e.g., hours, days, weeks, or months), for example, on different days. The present invention includes a method comprising sequentially administering to a patient a single initial dose of a GLP1 receptor agonist, followed by one or more second doses of a GLP1 receptor agonist, and optionally followed by one or more third doses of a GLP1 receptor agonist.

[0089] The terms "initial dose", "second dose" and "third dose" refer to the temporal order in which the GLP1 receptor agonist of the present invention is administered. Thus, the "initial dose" is the dose administered at the start of the treatment regimen (also referred to as the "baseline dose"); the "second dose" is the dose administered after the initial dose; and the "third dose" is the dose administered after the second dose. The initial dose, the second dose, and the third dose may all contain the same amount of GLP1 receptor agonist, but may generally differ from one another in the frequency of administration. However, in certain embodiments, during the course of treatment, the amount of GLP1 receptor agonist contained in the initial dose, the second dose, and / or the third dose differs from one another (e.g., appropriately adjusted upward or downward). In certain embodiments, one or more (e.g., 2, 3, 4, or 5) doses are administered as a "loading dose" at the start of the treatment regimen, followed by subsequent doses (e.g., "maintenance doses") administered at a lower frequency.

[0090] In certain exemplary embodiments of the invention, each second and / or third dose is administered 1 to 48 hours (e.g., 1, 1 1 / 2,2,2 1 / 2,3,3 1 / 2,4,4 1 / 2,5,5 1 / 2,6,6 1 / 2,7,7 1 / 2,8,8 1 / 2,9,9 1 / 2, 10, 10 1 / 2, 11, 11 1 / 2, 12, 121 / 2, 13, 13 1 / 2, 14, 14 1 / 2, 15, 15 1 / 2, 16, 16 1 / 2, 17, 17 1 / 2, 18, 18 1 / 2, 19, 19 1 / 2, 20, 20 1 / 2, 21, 21 1 / 2, 22, 22 1 / 2, 23, 23 1 / 2, 24, 24 1 / 2, 25, 25 1 / 2, 26, 26 1 / 2 or more) administration. The phrase "immediately preceding dose" as used herein refers to the dose of the GLP1 receptor agonist administered to the patient before the next dose in the sequence is administered without an intervening dose in the sequence of multiple administrations. In certain embodiments, each second and / or third dose is administered every day, every 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days after the immediately preceding dose. In certain embodiments, each second and / or third dose is administered every 0.5 week, 1 week, 2 weeks, 3 weeks, or 4 weeks after the immediately preceding dose.

[0091] The method according to this aspect of the invention may include administering to the patient any number of second and / or third doses of a GLP1 receptor agonist. For example, in certain embodiments, only a single second dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8 or more) second doses are administered to the patient. Similarly, in certain embodiments, only a single third dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8 or more) third doses are administered to the patient.

[0092] In certain embodiments of the present invention, the frequency of administering the second and / or third dose to a patient may vary during the course of the treatment regimen. The frequency of administration may also be adjusted during the course of treatment by a physician according to the needs of an individual patient after clinical examination.

[0093] dose

[0094] The amount of a GLP1 receptor agonist administered to a subject according to the methods of the present invention is generally a therapeutically effective amount. As used herein, the phrase "therapeutically effective amount" refers to an amount of a GLP1 receptor agonist that results in one or more of the following: (a) reducing high sugar levels to normal levels (e.g., pre-meal blood sugar levels of 80 to 130 mg / dL; and / or (b) a detectable improvement in one or more symptoms or signs of diabetes.

[0095] In the case of a GLP1 receptor agonist, a therapeutically effective amount can be from about 0.001 mg to about 100 mg, for example, about 0.001 mg, about 0.002 mg, about 0.003 mg, about 0.004 mg, about 0.005 mg, about 0.006 mg, about 0.007 mg, about 0.008 mg, about 0.009 mg, about 0.01 mg, about 0.02 mg, about 0.03 mg, about 0.04 mg, about 0.05 mg, about 0.06 mg, about 0.07 mg, about 0.08 mg, about 0.09 mg, about 0.1 mg, about 0.2 mg, about 0.3 mg In some embodiments, 0.005 mg to 50 mg, 0.005 mg to 30 mg, 0.005 mg to 10 mg, 0.1 mg to 10 mg, or 0.1 mg to 5 mg of a GLP1 receptor agonist is administered to a subject in need thereof.

[0096] The amount of GLP1 receptor agonist contained in each dose can be expressed as milligrams of antibody per kilogram of subject body weight (ie, mg / kg). For example, the GLP1 receptor agonist can be administered to a subject at a dose of about 0.0001 to about 100 mg / kg of subject body weight.

[0097] Selected implementation

[0098] In embodiment 1, the present invention provides a glucagon-like peptide 1 (GLP1) variant, which comprises a mature GLP1 (7-37) (SEQ ID NO: 4) having at least one amino acid modification, wherein the amino acid modification is selected from: (i) adding an amino acid to the N-terminus; and (ii) deleting an amino acid from the peptide sequence; wherein the GLP1 variant has enhanced resistance to proteolytic cleavage and / or enhanced blood sugar lowering ability.

[0099] In embodiment 2, the present invention provides the GLP1 variant described in embodiment 1, wherein the amino acid modification comprises adding an amino acid selected from alanine (Ala) and glutamine (Gln) to the N-terminus.

[0100] In embodiment 3, the present invention provides the GLP1 variant of embodiment 1 or 2, wherein the amino acid modification comprises adding Gln to the N-terminus.

[0101] In embodiment 4, the present invention provides the GLP1 variant of embodiment 1, wherein the amino acid modification comprises deleting histidine (His1) or alanine (Ala2) from SEQ ID NO:4.

[0102] In embodiment 5, the present invention provides the GLP1 variant of any one of embodiments 1 to 4, comprising an amino acid sequence selected from SEQ ID NO: 5, 6, 7 and 8.

[0103] In embodiment 6, the present invention provides the GLP1 variant described in embodiment 5, which comprises the amino acid sequence of SEQ ID NO:6.

[0104] In embodiment 7, the present invention provides a fusion protein comprising the GLP1 variant of any one of embodiments 1 to 6 fused to a stabilizing domain, wherein the stabilizing domain is an antigen binding protein or an antigen binding fragment thereof that specifically binds to a GLP1 receptor and comprises a heavy chain variable region (HCVR) and a light chain variable region (LCVR).

[0105] In embodiment 8, the present invention provides the fusion protein of embodiment 7, wherein the GLP1 variant is fused to the N-terminus or C-terminus of the HCVR of the antigen binding protein or antigen binding fragment thereof.

[0106] In embodiment 9, the present invention provides the fusion protein of embodiment 7, wherein the GLP1 variant is fused to the N-terminus or C-terminus of the LCVR of the antigen binding protein or antigen binding fragment thereof.

[0107] In embodiment 10, the present invention provides a fusion protein comprising the GLP1 variant of any one of embodiments 1 to 6 fused to a stabilizing domain, wherein the stabilizing domain is an immunoglobulin (Ig) or a fragment thereof.

[0108] In embodiment 11, the present invention provides the fusion protein of embodiment 11, which comprises an amino acid sequence selected from SEQ ID No: 9, 10, 11, 12 and 13.

[0109] In embodiment 12, the present invention provides a fusion protein comprising a GLP1 variant fused to a stabilizing domain, wherein the stabilizing domain is an antigen binding protein or an antigen binding fragment thereof, wherein the antigen binding protein or fragment thereof comprises a heavy chain variable region (HCVR) and a light chain variable region (LCVR).

[0110] In embodiment 13, the present invention provides the fusion protein of embodiment 12, wherein the GLP1 variant is fused to the N-terminus or C-terminus of the HCVR of the antigen binding protein or fragment thereof.

[0111] In embodiment 14, the present invention provides the fusion protein of embodiment 12, wherein the GLP1 variant is fused to the N-terminus or C-terminus of the LCVR of the antigen binding protein or fragment thereof.

[0112] In embodiment 15, the present invention provides a fusion protein according to any one of embodiments 12 to 14, wherein the antigen binding protein or fragment thereof specifically binds to the GLP1 receptor.

[0113] In embodiment 16, the present invention provides the fusion protein of any one of embodiments 12 to 15, which comprises the GLP1 variant of any one of the above embodiments.

[0114] In embodiment 17, the present invention provides a fusion protein according to any one of embodiments 12 to 16, wherein the GLP1 variant comprises an amino acid sequence selected from SEQ ID NO: 5, 6, 7 and 8.

[0115] In embodiment 18, the present invention provides the fusion protein of embodiment 16 or 17, wherein the GLP1 variant comprises the amino acid sequence of SEQ ID NO:6.

[0116] In embodiment 19, the present invention provides a GLP1 receptor agonist comprising a GLP1 variant, wherein the GLP1 variant is fused to a stabilizing domain, wherein the stabilizing domain is an antigen binding protein or an antigen binding fragment thereof, wherein the antigen binding protein or fragment thereof comprises a heavy chain variable region (HCVR) and a light chain variable region (LCVR).

[0117] In embodiment 20, the present invention provides the GLP1 receptor agonist of embodiment 19, wherein the GLP1 variant is fused to the N-terminus or C-terminus of the HCVR of the antigen binding protein or fragment thereof.

[0118] In embodiment 21, the present invention provides the GLP1 receptor agonist of embodiment 19, wherein the GLP1 variant is fused to the N-terminus or C-terminus of the LCVR of the antigen binding protein or fragment thereof.

[0119] In embodiment 22, the present invention provides a GLP1 receptor agonist according to any one of embodiments 19 to 21, wherein the antigen binding protein or fragment thereof specifically binds to the GLP1 receptor.

[0120] In embodiment 23, the present invention provides a GLP1 receptor agonist according to any one of embodiments 19 to 22, comprising the GLP1 variant according to embodiment 1.

[0121] In embodiment 24, the present invention provides a GLP1 receptor agonist according to any one of embodiments 19 to 23, wherein the GLP1 variant comprises an amino acid sequence selected from SEQ ID NO: 5, 6, 7 and 8.

[0122] In embodiment 25, the present invention provides the GLP1 receptor agonist of embodiment 23 or 24, wherein the GLP1 variant comprises the amino acid sequence of SEQ ID NO:6.

[0123] In embodiment 26, the present invention provides a GLP1 receptor agonist comprising a GLP1 variant, wherein the GLP1 variant is fused to a stabilizing domain, wherein the stabilizing domain is an immunoglobulin (Ig) or a fragment thereof.

[0124] In embodiment 27, the present invention provides the GLP1 receptor agonist of embodiment 26, which comprises an amino acid sequence selected from SEQ ID No: 9, 10, 11, 12 and 13.

[0125] In embodiment 28, the present invention provides a pharmaceutical composition comprising the protein of any one of embodiments 1 to 27 and a pharmaceutically acceptable carrier or diluent.

[0126] In embodiment 29, the present invention provides an isolated polynucleotide molecule comprising a polynucleotide sequence encoding the GLP1 variant of any one of embodiments 1 to 6.

[0127] In embodiment 30, the present invention provides an isolated polynucleotide molecule comprising a polynucleotide sequence encoding the fusion protein of any one of embodiments 10 to 11.

[0128] In embodiment 31, the present invention provides an isolated polynucleotide molecule comprising a polynucleotide sequence encoding the GLP1 receptor agonist of any one of embodiments 26 to 27.

[0129] In embodiment 32, the present invention provides a vector comprising the polynucleotide sequence of any one of embodiments 29 to 31.

[0130] In embodiment 33, the present invention provides a cell expressing the vector of embodiment 32.

[0131] In embodiment 34, the present invention provides a method for lowering blood glucose levels, comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of the protein of any one of embodiments 1 to 27.

[0132] In embodiment 35, the present invention provides the method of embodiment 34, wherein the subject suffers from a disease or condition selected from the group consisting of diabetes, obesity, insulin resistance, hypertension, dyslipidemia, type 2 diabetes, type 1 diabetes, prediabetes, cardiovascular disease, atherosclerosis, congestive heart failure, coronary heart disease, arteriosclerosis, peripheral arterial disease, stroke, respiratory dysfunction, kidney disease, fatty liver disease, non-alcoholic steatohepatitis (NASH) and metabolic syndrome.

[0133] In embodiment 36, the present invention provides a method for preventing, treating or ameliorating at least one symptom, indication or complication of type 2 diabetes, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of the protein described in any one of embodiments 1 to 27.

[0134] In embodiment 37, the present invention provides the method of embodiment 36, wherein the at least one symptom, indication or complication is selected from: high blood sugar levels, excessive thirst, polyuria, presence of ketone bodies in urine, fatigue, weight fluctuations, blurred vision, slow healing of sores, frequent infections, swollen or painful gums, obesity, heart disease, stroke, kidney disease, eye disease, nerve damage and high blood pressure.

[0135] In embodiment 38, the present invention provides the method of any one of embodiments 34 to 37, wherein the pharmaceutical composition is administered in combination with a second therapeutic agent or treatment.

[0136] In embodiment 39, the present invention provides the method of embodiment 38, wherein the second therapeutic agent or treatment is selected from: insulin or insulin analogs, biguanides (e.g., metformin), thiazolidinediones, sulfonylureas (e.g., chlorpropamide), glinides (e.g., nateglinide), alpha-glucosidase inhibitors, DPP4 inhibitors (e.g., sitagliptin), pramlintide, bromocriptine, SGLT2 inhibitors (e.g., canagliflozin), antihypertensive drugs, statins, aspirin, dietary modification, exercise and dietary supplements.

[0137] In embodiment 40, the present invention provides the method of any one of embodiments 34 to 39, wherein the pharmaceutical composition is administered subcutaneously, intravenously, intradermally, intraperitoneally, orally or intramuscularly.

[0138] Example

[0139] The following examples are presented to provide a person of ordinary skill in the art with a complete disclosure and description of how to prepare and use the methods and compositions of the present invention, and are not intended to limit the scope of what the inventors regard as their invention. Every effort has been made to ensure the accuracy of the numbers used (e.g., amounts, temperatures, etc.), but some experimental errors and deviations should be considered. Unless otherwise indicated, parts are parts by weight, molecular weights are average molecular weights, temperatures are in degrees Celsius, room temperature is approximately 25°C, and pressures are at or near atmospheric pressure.

[0140] Example 1: Exemplary Fusion Proteins Comprising GLP1

[0141] GLP1 (7-37) has a very short circulating half-life (1 to 2 minutes) due to rapid inactivation by the enzyme dipeptidyl peptidase 4 (DPP4). Previous studies have shown that various amino acid substitutions at position 8 of GLP1 (7-37) render it more resistant to DPP4, thereby conferring a longer half-life (Deacon et al 1998, Diabetologia 41: 271-278). However, these molecules have residual sensitivity to DPP4 cleavage. Therefore, there is a need to develop new molecules that are still more resistant to DPP4.

[0142] To confer better resistance to DPP4, the first part of the technology is to introduce mutations that extend or shorten the amino terminus of GLP1 by adding amino acids to the N-terminus (i.e., A1a, G1n) or deleting His7 or A1a8 in the peptide sequence to provide better resistance to DPP4 cleavage. These modifications also weaken the activity of GLP1, and the second part of the technology is to compensate for the reduced activity by using a GLP1R antibody to connect the weakened agonist to the receptor, which is done by fusing the peptide to the N-terminus of the anti-GLP1R antibody light chain sequence. As a proof of concept, the modified GLP1 (7-37) ligand sequence was fused to the N-terminus of the light chain of the GLP1R antibody as described below.

[0143] Mature GLP1 is a 31-amino acid peptide hormone that comprises amino acids 7 to 37 of full-length GLP1 (SEQ ID NO: 3) and has the amino acid sequence: HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG (SEQ ID NO: 4).

[0144] Mature GLP1 is modified by deletion or addition of amino acids at the amino terminus to produce GLP1 variants. Exemplary GLP1 variants are given below:

[0145] Des-A1a-GLP1, which comprises the amino acid sequence:

[0146] HEGTFTSDVSSYLEGQAAKEFIAWLVKGRG(SEQ ID NO: 5)

[0147] Q-GLP1, comprising the amino acid sequence:

[0148] QHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG(SEQ ID NO: 6)

[0149] A-GLP1, comprising the amino acid sequence:

[0150] AHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG (SEQ ID NO: 7)

[0151] desH-GLP1, comprising the sequence: AEGTFTSDVSSYLEGQAAKEFIAWLVKGRG (SEQ ID NO: 8)

[0152] In order to compensate for the possible reduced activity of the above-mentioned GLP1 variants, anti-GLP1R antibodies are used to link them to the GLP1 receptor (GLP1R) or to the antibody Fc fragment. Exemplary fusion proteins comprising mature GLP1 or GLP1 variants are generated by fusing mature GLP1 or GLP1 variants to the N-terminus of the light chain of an anti-GLP1 receptor antibody (hereinafter referred to as "mAb1"; U.S. Patent Application Publication No. 20060275288 [Abbott Laboratories]) comprising a heavy chain variable region of SEQ ID NO: 2 and a light chain variable region (LCVR) of SEQ ID NO: 1, and are listed below:

[0153] Des-A1a-GLP1-mAb1: Des-A1a-GLP1 fused to the N-terminus of the mAb1 light chain (SEQ ID NO: 5)

[0154] Q-GLP1-mAb1: Q-GLP1 fused to the N-terminus of the mAb1 light chain (SEQ ID NO: 6)

[0155] A-GLP1-mAb1: A-GLP1 fused to the N-terminus of the mAb1 light chain (SEQ ID NO: 7)

[0156] Fusion proteins comprising mature GLP1 or GLP1 variants and immunoglobulin Fc fragments were also produced and are listed below:

[0157] GLP1-hFc (SEQ ID NO: 9)

[0158] A-GLP1-hFc (SEQ ID NO: 10)

[0159] Q-GLP1-hFc (SEQ ID NO: 11)

[0160] ·Des-A1a-GLP1-hFc (SEQ ID NO: 12)

[0161] ·desH-GLP1-hFc (SEQ ID NO: 13)

[0162] Control construct Comparison : A GLP1 analogue (dulaglutide; Eli Lilly) having an amino acid sequence characteristic of LY2189265 fused to a hIgG4 Fc domain disclosed by Glaesner et al. 2010 (Diabetes Metab. Res. Rev. 26: 287-296) was used as a comparator (SEQ ID NO: 14) in the following examples.

[0163] Example 2: Luciferase Assay

[0164] The ability of GLP1 fusion proteins to stimulate cAMP production was tested in the reporter cell line 293 / FSC11 / Cre-Luc, which stably expresses the human GLP1 receptor and the luciferase coding sequence under the control of the cAMP-responsive cre promoter.

[0165] For the luciferase bioassay, 293 / FSC11 / Cre-Luc GLP1R stable cells were seeded into 96-well assay plates at 30,000 cells / well in OPTIMEM supplemented with 0.1% FBS and then incubated overnight at 37°C in 5% CO2. The next day, to determine the dose response of the test protein, human GLP1 (Phoenix #028-13), des-Ala-GLP1-mAb1, Q-GLP1-mAb1, or A-GLP1-mAb1 were tested in the assay. All test compounds except A-GLP1-mAb1 were purified proteins, and A-GLP1-mAb1 was used directly from the culture medium after transient transfection of CHO cells with a vector encoding the modified antibody. The material in the culture medium was quantified by ELISA. The test samples were added to the cells at concentrations ranging from 0.02pM to 100nM.

[0166] After incubation at 37°C for 5.5 hours or overnight in 5% CO2, OneGlo reagent (Promega, #E6051) was added to the samples and luciferase activity was measured using a Victor X (Perkin Elmer) plate reader. The results were analyzed using nonlinear regression (three parameters) with Prism 6 software (GraphPad) to obtain EC 50 value.

[0167] As shown in Table 1, for GLP1R activation, the Q-modified mAb1 antibody fusion and the A-modified mAb1 antibody fusion showed EC50 values ​​of 204 pM and 312 pM, respectively.

[0168] Table 1: EC50 of GLP1 fusion proteins

[0169] GLP1 fusion protein EC50 des-A1a-GLP1-mAb1 10nM Q-GLP1-mAb1 0.204nM A-GLP1-mAb1 0.312nM GLP1-hFc 0.147nM A-GLP1-hFc 120nM Q-GLP1-hFc 135nM Des-Ala-GLP1-hFc Undetectable Des-H-GLP1-hFc 2560nM Comparison 0.059nM

[0170] The EC50 of des-Ala-GLP1-mAb1 was 10 nM. The EC50s of Q- and A-GLP1-hFc were only 135 nM and 120 nM, while the EC50 of Des A-GLP1-hFc was undetectable.

[0171] Example 3: Effects of Q-GLP1 fused to GLP1R antibody on blood glucose and glucose tolerance in GLP1R humanized mice

[0172] The effects of Q-GLP1 fused to the N-terminus of the light chain of an anti-GLP1R antibody (Q-GLP1-mAb1) on blood glucose and glucose tolerance were determined in genetically modified mice expressing human GLP1R protein ("GLP1R humanized mice"). 31 GLP1R humanized mice were divided into four groups of 7 to 8 animals. Each group received a single subcutaneous injection of 194nmol / kg of isotype control, Q-GLP1-hFc, mAb1, or Q-GLP1-mAb1. Mice were bled under fed conditions on days 0, 1, 4, 7, 11, 14, 16, 18, and 22 for blood glucose measurement. The mean ± SEM of blood glucose levels for each group at each time point was calculated and is shown in Table 2.

[0173] Table 2: Blood glucose levels

[0174]

[0175] Oral glucose tolerance test (oGTT) was performed after overnight fasting on days 3 and 9, with blood glucose measurements at 0, 15, 30, 60 and 120 minutes after bolus glucose gavage. The mean ± SEM of blood glucose levels and the area under the blood glucose curve (AUC) were calculated for each group at each time point and are shown in Tables 3 and 4.

[0176] Table 3: Blood glucose levels and blood glucose AUC on day 3

[0177]

[0178] Table 4: Blood glucose levels and blood glucose AUC on day 9

[0179]

[0180] A single administration of Q-GLP1-mAb1 in normoglycemic GLP1R humanized mice resulted in a significant decrease in glucose for 14 days, whereas Q-GLP1-hFc or mAb1 did not affect blood glucose levels (Table 2). Q-GLP1-mAb1 reduced fasting blood glucose levels and improved glucose tolerance on days 3 and 9 in mice, whereas Q-GLP1-hFc and mAb1 did not. These data suggest that Q-GLP1 or mAb1 antibodies alone do not alter glycemic control, but that a fusion molecule of the two can exert a glucose-lowering effect that persists for 2 weeks in normoglycemic animals following a single injection.

[0181] Example 4: Stability of GLP1 variants

[0182] The stability of various GLP1 variants and fusion proteins was tested by incubating them with serum proteases and analyzing the cleaved peptides by mass spectrometry.

[0183] In the first experiment, 0.5 μg of each GLP1 fusion protein was added to 50 μL of untreated mouse serum. The mixture was then incubated at 37°C for 6 hours and 24 hours. 1 μL of the serum mixture at 0 minutes, 6 hours, and 24 hours was loaded on a Tris-glycine gel.

[0184] In a second experiment, to further differentiate stability, 2 μg of each GLP1 fusion protein was incubated with 500 ng of recombinant human DPP4 (R&D Systems) in PBS (pH 7.4) at 37° C. for 0 min, 1 h, 4 h, and 72 h. One fifth of the above mixture (equivalent to 400 ng of the construct) was loaded onto a Tris-glycine gel.

[0185] For each experiment, the gel portion corresponding to the molecular weight of each construct was cut and in-gel trypsin digestion was performed. The cut gel fragments were decolorized in 50:50 acetonitrile: NH4HCO3 (50mM), reduced with 65mM dithiothreitol (Sigma) at 37°C for 30 minutes, and then alkylated with 135mM iodoacetamide (Sigma) in the dark for 30 minutes at room temperature. Subsequently, the protein was digested overnight with sequencing-grade modified porcine trypsin (Promega) at 37°C. The peptides were extracted twice with extraction buffer (50% ACN, 5% formic acid in H2O). The peptides extracted from each band were dried to completion in SpeedVac and reconstructed with 0.1% tetrafluoroacetic acid (TFA) before nanoLC-MS / MS analysis.

[0186] The reconstituted peptide mixture was separated by online reverse phase (RP) nanocapillary liquid chromatography (Easy-nLC1000, Thermo Fisher Scientific) and analyzed by electrospray tandem mass spectrometry (Orbitrap Elite, Thermo Fisher Scientific). The peptide mixture was injected into a "PepMap RSLC" column (C18, 25 cm, 1.3 cm) with an inner diameter of 75 μm at a flow rate of 250 nL / min. 2μm, Thermo Fisher Scientific), and then eluted with 2% to 35% ACN in 0.1% formic acid in a 60 minute gradient. The mass spectrometer is operated in data-dependent mode to automatically switch between MS and MS / MS acquisitions. Full scan MS spectra (from m / z350 to 2000) are measured in Orbitrap at a resolution of 120,000. Fragmentation in a hybrid ion trap using collision induced dissociation (CID) at a normalized collision energy of 35% with a target value of 5000 is performed, and the strongest ions (up to ten) are successively separated. The target ions selected for MS / MS are dynamically excluded for 30 seconds.

[0187] Extract MS and MS / MS peak lists and use ProteomeDiscoverer 1.4 (Thermo Fisher Scientific) to search against internal protein database. All searches assume that trypsin digestion is adopted, and it is considered that the carboxymethylation of cysteine ​​is a fixed modification and the oxidation of methionine is a variable modification. Used a peptide mass tolerance of 10ppm, an MS / MS mass tolerance of 0.8Da, and a limit of up to 1 wrong cutting. Use Thermo Xcaliber software (Thermo Fisher Scientific) to calculate the extracted ion area based on the extracted ion chromatogram (extracted ion chromatogram, XIC).

[0188] result

[0189] To characterize the sensitivity of each construct to serum enzyme cleavage, the intact peptide (N-terminal peptide), cleaved peptide (N-terminal peptide after cleavage), and an internal reference peptide (a stable peptide insensitive to any modification in the construct) of each construct were monitored by nanoLC-MS / MS. A decrease in the ratio of intact peptide relative to the reference peptide and a simultaneous increase in the ratio of cleaved peptide relative to the reference peptide indicate enzyme-mediated cleavage of the construct over time. The cleavage percentage was calculated using the following formula: 100×cleaved peptide area / (cleaved peptide area+uncleaved peptide area)

[0190] GLP1-hFc and A-GLP1-hFc were completely cleaved by 6 hours, while desH-GLP1-hFc showed significant cleavage (2%) by 6 hours. After 24 hours of incubation, Q-GLP1-hFc and the comparator did not show any cleavage (Table 5).

[0191] Table 5: Percent cleavage of selected GLP1 receptor agonists

[0192] % Cut in 6 hours % Cut in 24 hours GLP1-hFc 100% 100% desH-GLP1-hFc 2% 5% Q-GLP1-hFc 0% 0% A-GLP1-hFc 100% 100% Comparison 0% 0%

[0193] To further differentiate the stability of Q-GLP1-hFc and comparators, both constructs were mixed with recombinant human DPP4, and intact peptide (N-terminal peptide), cleaved peptide (N-terminal peptide after cleavage), and an internal reference peptide (a stable peptide insensitive to any modification in the construct) of either construct were monitored by nanoLC-MS / MS.

[0194] Table 6: Stability of selected GLP1 receptor agonists against DPP4

[0195] % Cut after 4 hours % cut after 72 hours Q-GLP1-hFc 0% 0% Comparison 4% 41%

[0196] The comparator showed significant cleavage by 4 hours (4%) and more than 40% cleavage by 72 hours (Table 6). In contrast, Q-GLP1-hFc did not show any cleavage even after 72 hours of incubation with DPP4 at 37°C.

[0197] The scope of the present invention is not limited to the specific embodiments described herein. In fact, in addition to those described herein, various modifications of the present invention will also become apparent to those skilled in the art based on the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

[0198] The original claims of the parent case of this application are incorporated herein as part of this specification:

[0199] 1. A fusion protein comprising a glucagon-like peptide 1 (GLP1) variant, wherein the GLP1 variant comprises mature GLP1 (7-37) (SEQ ID NO: 4) with amino acids added to the N-terminus, wherein the fusion protein has enhanced resistance to proteolytic cleavage and / or enhanced blood sugar lowering ability.

[0200] 2. The fusion protein of claim 1, wherein the amino acid is selected from alanine (Ala) and glutamine (Gln).

[0201] 3. The fusion protein of claim 1 or 2, wherein the amino acid comprises Gln.

[0202] 4 . The fusion protein of claim 1 , wherein the GLP1 variant comprises an amino acid sequence selected from SEQ ID NO: 6 and 7. 4 .

[0203] 5. The fusion protein of any one of claims 1 to 4, wherein the GLP1 variant comprises the amino acid sequence of SEQ ID NO: 6.

[0204] 6. The fusion protein of any one of claims 1 to 5, further comprising a stabilizing domain, wherein the stabilizing domain is an antigen binding protein or an antigen binding fragment thereof that specifically binds to the GLP1 receptor and comprises a heavy chain variable region (HCVR) and a light chain variable region (LCVR).

[0205] 7. The fusion protein of claim 6, wherein the GLP1 variant is fused to the N-terminus or C-terminus of the HCVR of the antigen binding protein or antigen binding fragment thereof.

[0206] 8. The fusion protein of claim 6, wherein the GLP1 variant is fused to the N-terminus or C-terminus of the LCVR of the antigen binding protein or antigen binding fragment thereof.

[0207] 9. The fusion protein of any one of claims 6 to 8, wherein the stabilizing domain is an antibody or a fragment thereof.

[0208] 10. A fusion protein comprising a glucagon-like peptide 1 (GLP1) variant fused to a stabilizing domain, wherein: (i) the GLP1 variant comprises mature GLP1 (7-37) (SEQ ID NO: 4) with glutamine (Gln) added to the N-terminus; (ii) the stabilizing domain is an antigen binding protein or an antigen binding fragment thereof that specifically binds to the GLP1 receptor; and (iii) the fusion protein has enhanced resistance to proteolytic cleavage and / or enhanced blood sugar lowering ability.

[0209] 11. The fusion protein of claim 10, wherein the stabilizing domain is an antibody or antigen-binding fragment thereof comprising HCVR and LCVR.

[0210] 12. The fusion protein of claim 11, wherein the GLP1 variant is fused to the N-terminus of the LCVR of the antibody or antigen-binding fragment thereof.

[0211] 13. The fusion protein of any one of claims 10 to 12, wherein the GLP1 variant comprises the amino acid sequence of SEQ ID NO: 6.

[0212] 14. A pharmaceutical composition comprising the fusion protein of any one of claims 1 to 13 and a pharmaceutically acceptable carrier or diluent.

[0213] 15. An isolated polynucleotide molecule comprising a polynucleotide sequence encoding the fusion protein as described in any one of claims 1 to 13.

[0214] A vector comprising the polynucleotide sequence of claim 15 .

[0215] 17. A cell expressing the vector of claim 16.

[0216] 18. A method for lowering blood glucose levels, comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of the protein of any one of claims 1 to 13.

[0217] 19. The method of claim 18, wherein the subject has a disease or condition selected from the group consisting of diabetes, obesity, insulin resistance, hypertension, dyslipidemia, type 2 diabetes, type 1 diabetes, prediabetes, cardiovascular disease, atherosclerosis, congestive heart failure, coronary heart disease, arteriosclerosis, peripheral arterial disease, stroke, respiratory dysfunction, kidney disease, fatty liver disease, nonalcoholic steatohepatitis (NASH), and metabolic syndrome.

[0218] 20. A method for preventing, treating or ameliorating at least one symptom, indication or complication of type 2 diabetes, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of the protein of any one of claims 1 to 13.

[0219] 21. The method of claim 20, wherein the at least one symptom, indication, or complication is selected from the group consisting of high blood sugar levels, excessive thirst, polyuria, the presence of ketones in the urine, fatigue, weight fluctuations, blurred vision, slow healing of sores, frequent infections, swollen or painful gums, obesity, heart disease, stroke, kidney disease, eye disease, nerve damage, and high blood pressure.

[0220] 22. The method of any one of claims 18 to 21, wherein the pharmaceutical composition is administered in combination with a second therapeutic agent or treatment.

[0221] 23. The method of claim 22, wherein the second therapeutic agent or treatment is selected from the group consisting of insulin or insulin analogs, metformin, thiazolidinediones, sulfonylureas, biguanides, chlorpropamide, glinides, alpha glucosidase inhibitors, nateglinide, DPP4 inhibitors, pramlintide, sitagliptin, bromocriptine, SGLT2 inhibitors, canagliflozin, antihypertensives, statins, aspirin, dietary modification, exercise, and dietary supplements.

[0222] 24. The method of any one of claims 18 to 23, wherein the pharmaceutical composition is administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, or intramuscularly.

Claims

1. A fusion protein consisting of the amino acid sequence shown in SEQ ID NO:

11.

2. A pharmaceutical composition comprising the fusion protein according to claim 1 and a pharmaceutically acceptable carrier or diluent.

3. A needle and a syringe comprising the fusion protein of claim 1 or the pharmaceutical composition of claim 2.

4. A pen delivery device comprising the fusion protein of claim 1 or the pharmaceutical composition of claim 2.

5. An automatic injector comprising the fusion protein of claim 1 or the pharmaceutical composition of claim 2.

6. The pharmaceutical composition of claim 2, wherein the pharmaceutical composition is sterile and aqueous.

7. The pharmaceutical composition of claim 2, wherein the pharmaceutical composition is an isotonic solution.

8. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition comprises glucose.

9. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition further comprises one or more agents selected from alcohols, polyols and nonionic surfactants.

10. The pharmaceutical composition of claim 9, wherein the nonionic surfactant is polysorbate 80.

Citation Information

Patent Citations

  • Glucagon-like peptide-1 receptor (GLP-1r) agonists for treating autoimmune disorders

    EP2470198A2

  • GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof

    US20060275288A1

  • Glucagon-like protein-1 receptor (GLP-1r) agonists for treating autoimmune disorders

    US20120148586A1

  • Fusion proteins for treating a metabolic syndrome

    US20140073563A1

  • Methods for treating and / or limiting development of diabetes

    US20150259416A1